Press release
Alzheimer's Disease Clinical Trials, Companies, Therapeutic Assessment, Emerging, Treatment Algorithm, Pipeline | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeu
Alzheimer's Disease Clinical Trials
DelveInsight's analysis highlights that the Alzheimer's Disease pipeline comprises over 110 key companies actively engaged in developing more than 120 treatment therapies.
Alzheimer's Disease Overview:
Alzheimer's disease (AD) is a neurodegenerative disorder that causes the progressive deterioration of brain cells and is the leading cause of dementia, characterized by cognitive decline and the loss of independence in daily life. AD is considered a multifactorial condition, with two primary hypotheses proposed for its development: the cholinergic hypothesis and the amyloid hypothesis. Several risk factors also contribute to its onset, including aging, genetic predisposition, head trauma, vascular conditions, infections, and environmental influences.
The symptoms of Alzheimer's disease vary with disease stage. Based on the severity of cognitive decline, AD is categorized into preclinical (presymptomatic), mild, and dementia-stage, which differ from the DSM-5 classification of the condition.
The earliest and most common symptom is episodic short-term memory loss, while long-term memory is often preserved in the early stages. As the disease progresses, patients may experience difficulties with problem-solving, judgment, executive functioning, and motivation, leading to issues with multitasking and abstract thinking. Executive dysfunction in the early phase may range from mild to severe.
Request for a detailed insights report on Alzheimer's Disease pipeline insights [https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Alzheimer's Disease Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Alzheimer's Disease Therapeutics Market.
Key Takeaways from the Alzheimer's Disease Pipeline Report
*
DelveInsight's Alzheimer's Disease pipeline report highlights a dynamic landscape, featuring over 110 active companies developing more than 120 therapeutic candidates for Alzheimer's treatment. Leading industry players, including AriBio, Eli Lilly, Cognition Therapeutics, AbbVie, Allyx Therapeutics, Cassava Sciences, BioVie, Novo Nordisk, Alector, Longeveron, TrueBinding, VT BIO, Luye Pharma, Lexeo Therapeutics, Merck, Regeneration Biomedical, Alnylam, Sinotau Pharmaceutical, Eisai, Shanghai Hengrui, and others, are advancing novel therapies to enhance the treatment paradigm.
*
Notable pipeline candidates in various stages of development include AR1001, NE3107, LY3372689, CT1812, ABBV-916, ALX-001, and more.
*
In July 2024, the U.S. FDA approved Kisunla Trademark (donanemab-azbt) for adults with early symptomatic Alzheimer's disease. Clinical studies demonstrated a 35% reduction in cognitive and functional decline over 18 months compared to placebo and a 39% lower risk of progression to the next disease stage. Kisunla is notable for its limited-duration treatment regimen, with nearly half of the study participants completing the course within 12 months.
Alzheimer's Disease Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Alzheimer's Disease Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer's Disease treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Alzheimer's Disease market.
Download our free sample page report on Alzheimer's Disease pipeline insights [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Alzheimer's Disease Emerging Drugs
*
AR1001: AriBio Co., Ltd.
*
NE3107: BioVie
*
LY3372689: Eli Lilly & Co.
*
CT1812: Cognition Therapeutics
*
ABBV-916: AbbVie Inc.
*
ALX-001: Allyx Therapeutics, Inc.
Alzheimer's Disease Companies
Over 110 leading companies are currently working on developing therapies for Alzheimer's disease, with AriBio Co., Ltd. and BioVie having candidates in the most advanced stage, currently in Phase III clinical trials.
DelveInsight's report covers around 120+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Alzheimer's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Alzheimer's Disease Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Alzheimer's Disease Therapies and Key Companies: Alzheimer's Disease Clinical Trials and advancements [https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Alzheimer's Disease Pipeline Therapeutic Assessment
- Alzheimer's Disease Assessment by Product Type
- Alzheimer's Disease By Stage
- Alzheimer's Disease Assessment by Route of Administration
- Alzheimer's Disease Assessment by Molecule Type
Download Alzheimer's Disease Sample report to know in detail about the Alzheimer's Disease treatment market @ Alzheimer's Disease Therapeutic Assessment [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Alzheimer's Disease Current Treatment Patterns
4. Alzheimer's Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Alzheimer's Disease Late-Stage Products (Phase-III)
7. Alzheimer's Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Alzheimer's Disease Discontinued Products
13. Alzheimer's Disease Product Profiles
14. Alzheimer's Disease Key Companies
15. Alzheimer's Disease Key Products
16. Dormant and Discontinued Products
17. Alzheimer's Disease Unmet Needs
18. Alzheimer's Disease Future Perspectives
19. Alzheimer's Disease Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Alzheimer's Disease Pipeline Reports Offerings [https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alzheimers-disease-clinical-trials-companies-therapeutic-assessment-emerging-treatment-algorithm-pipeline-aribio-co-ltd-eli-lilly-co-cognition-therapeutics-abbvie-inc-allyx-therapeu]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Clinical Trials, Companies, Therapeutic Assessment, Emerging, Treatment Algorithm, Pipeline | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeu here
News-ID: 4158964 • Views: …
More Releases from ABNewswire
Psychosis in Parkinson's and Alzheimer's Disease Market: Epidemiology, Pipeline …
According to DelveInsight's analysis, the psychosis in Parkinson's disease and Alzheimer's disease market in the 7MM was valued at approximately USD 1,290 million in 2023 and is projected to grow over the forecast period from 2024 to 2034.
Emerging therapies for psychosis in Parkinson's and Alzheimer's disease, including NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others, are expected to drive significant growth in the market in the coming years.
DelveInsight has…
Focal Epilepsy Market: Epidemiology, Pipeline, Companies, DelveInsight | Biocode …
The Focal Epilepsy Market has seen notable advancements in recent years, driven by an increasing understanding of disease pathology, emerging treatment options, and ongoing research in novel therapeutics.
Focal Epilepsy therapies are expected to boost the Focal Epilepsy Market in the upcoming years.
DelveInsight has launched a new report on "Focal Epilepsy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Focal Epilepsy, historical and forecasted epidemiology…
Agitation in Alzheimer's Disease Market: Epidemiology, Pipeline, Companies Worki …
The Agitation in Alzheimer's Disease market size is projected to experience a consistent CAGR during the forecast period (2024-2034), due to several factors. The key driver is an increase in the aging population, particularly in developed countries where the prevalence of Alzheimer's disease is higher.
Emerging therapies for Agitation in Alzheimer's Disease, including TransCon hGH, HyTropin (GX-H9), Somatrogon, and others, are anticipated to drive significant growth in the market over the…
Cell and Gene Therapy in Parkinson's Disease Clinical Trials, Companies, Therape …
DelveInsight's, "Cell and Gene Therapy in Parkinson's Disease - Pipeline Insight, 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Cell and Gene Therapy in Parkinson's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
DelveInsight's analysis highlights that the Cell and Gene Therapy pipeline…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
